ContractLicense Agreement • March 20th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations
[*] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
LICENSE AND COLLABORATION AGREEMENT BY AND BETWEEN TAKEDA PHARMACEUTICAL COMPANY LIMITED AND OVID THERAPEUTICS INC. JANUARY 6, 2017License and Collaboration Agreement • March 20th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
This License and Collaboration Agreement (this “Agreement”) is made effective as of January 6, 2017 (the “Effective Date”) by and between Takeda Pharmaceutical Company Limited, a company incorporated under the laws of Japan having its principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“Takeda”) and Ovid Therapeutics Inc., a company incorporated under the laws of the State of Delaware having its principal place of business at 1460 Broadway, New York, NY 10036, U.S.A. (“Ovid”). Ovid and Takeda are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENTVoting Agreement • March 20th, 2017 • Ovid Therapeutics Inc. • Pharmaceutical preparations • New York
THIS SERIES B-1 PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the 6th day of January, 2017 by and among Ovid Therapeutics Inc., a Delaware corporation (the “Company”), and Takeda Pharmaceutical Company Limited (the “Purchaser”).
